👤 Xin-Ming Chen

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
2981
Articles
1996
Name variants
Also published as: Wen-Chau Chen, Jingzhao Chen, Dexi Chen, Haifeng Chen, Chung-Jen Chen, Bo-Jun Chen, Gao-Feng Chen, Changyan Chen, Weiwei Chen, Fenghua Chen, Xiaojiang S Chen, Xiu-Juan Chen, Jung-Sheng Chen, Xiao-Ying Chen, Chong Chen, Junyang Chen, YiPing Chen, Xiaohan Chen, Li-Zhen Chen, Jiujiu Chen, Shin-Wen Chen, Guangping Chen, Dapeng Chen, Ximei Chen, Renwei Chen, Jianfei Chen, Yulu Chen, Yu-Chi Chen, Jia-De Chen, Rongfang Chen, She Chen, Zetian Chen, Tianran Chen, Emily Chen, Baoxiang Chen, Ya-Chun Chen, Dongxue Chen, Wei-xian Chen, Danmei Chen, Ceshi Chen, Junling Chen, Xia Chen, Daoyuan Chen, Yongbin Chen, Chi-Yu Chen, Dian Chen, Xiuxiu Chen, Bo-Fang Chen, Fangyuan Chen, Jin-An Chen, Xiaojuan Chen, Zhuohui Chen, Junqi Chen, Lina Chen, Fangfang Chen, Hanwen Chen, Yilei Chen, Po-Han Chen, Xiaoxiang Chen, Jimei Chen, Guochong Chen, Yanyun Chen, Yifei Chen, Cheng-Yu Chen, Zi-Jiang Chen, Jiayuan Chen, Miaoran Chen, Junshi Chen, Yu-Ying Chen, Pengxiang Chen, Hui-Ru Chen, Yupeng Chen, Ida Y-D Chen, Xiaofeng Chen, Qiqi Chen, Shengnan Chen, Mao-Yuan Chen, Lizhu Chen, Weichan Chen, Xiang-Bin Chen, Hanxi Chen, Sulian Chen, Zoe Chen, Minghong Chen, Chi Chen, Yananlan Chen, Yanzhu Chen, Shiyi Chen, Ze-Xu Chen, Zhiheng Chen, Jia-Mei Chen, Shuqin Chen, Yi-Hau Chen, Danni Chen, Donglong Chen, Xiaomeng Chen, Yidong Chen, Keyu Chen, Hao Chen, Junmin Chen, Wenlong Chen, Yufei Chen, Wanbiao Chen, Mo Chen, Youjia Chen, Xin-Jie Chen, Lanlan Chen, Huapu Chen, Shuaiyin Chen, Jing-Hsien Chen, Hengsheng Chen, Bing-Bing Chen, Fa-Xi Chen, Zhiqiang Chen, Ming-Huang Chen, Liangkai Chen, Li-Jhen Chen, Zhi-Hao Chen, Yinzhu Chen, Guanghong Chen, Gaozhi Chen, Jiakang Chen, Yongke Chen, Guangquan Chen, Li-Hsien Chen, Yiduo Chen, Zongnan Chen, Jing Chen, Meilan Chen, Jin-Shuen Chen, Huanxiong Chen, Yann-Jang Chen, Guozhong Chen, Yu-Bing Chen, Xiaobin Chen, Catherine Qing Chen, Youhu Chen, Hui Mei Chen, L F Chen, Haiyang Chen, Ruilin Chen, Peng Chen, Kailang Chen, Chao Chen, Suipeng Chen, Zemin Chen, Jianlin Chen, Shang-Chih Chen, Yen-Hsieh Chen, Jia-Lin Chen, Chaojin Chen, Minglang Chen, Xiatian Chen, Zeyu Chen, Kang Chen, Mei-Chi Chen, Jihai Chen, Pei Chen, Defang Chen, Zhao Chen, Tianrui Chen, Tingtao Chen, Caressa Chen, Jiwei Chen, Xuerong Chen, Yizhi Chen, XueShu Chen, Mingyue Chen, Huichao Chen, Chun-Chi Chen, Xiaomin Chen, Hetian Chen, Yuxing Chen, Jie-Hua Chen, Chuck T Chen, Yuanjia Chen, Hong Chen, Jianxiong Chen, S Chen, D M Chen, Jiao-Jiao Chen, Gongbo Chen, Xufeng Chen, Xiao-Jun Chen, Harn-Shen Chen, Qiu Jing Chen, Tai-Heng Chen, Pei-Lung Chen, Kaifu Chen, Huang-Pin Chen, Tse-Wei Chen, Yanrong Chen, Xianfeng Chen, Chung-Yung Chen, Yuelei Chen, Qili Chen, Guanren Chen, TsungYen Chen, Yu-Si Chen, Junsheng Chen, Min-Jie Chen, Jiabing Chen, Sili Chen, Qinying Chen, Yue Chen, Lin Chen, Xiaoli Chen, Zhuo Chen, Aoshuang Chen, Junyu Chen, Chunji Chen, Yian Chen, Shanchun Chen, Shuen-Ei Chen, Canrong Chen, Shih-Jen Chen, Yaowu Chen, Han Chen, Yih-Chieh Chen, Wei-Cong Chen, Yanfen Chen, Tao Chen, Huangtao Chen, Jingyi Chen, Sheng Chen, Jing-Wen Chen, Gao Chen, Lei-Lei Chen, Kecai Chen, Yao-Shen Chen, Haiyu Chen, W Chen, Xiaona Chen, Cheng-Sheng Chen, X R Chen, Shuangfeng Chen, Jingyuan Chen, Xinyuan Chen, Huanhuan Chen, Mengling Chen, Liang-Kung Chen, Ming-Huei Chen, Hongshan Chen, Cuncun Chen, Qingchao Chen, Yanzi Chen, Lingli Chen, Shiqian Chen, Liangwan Chen, Lexia Chen, Wei-Ting Chen, Zhencong Chen, Tzy-Yen Chen, Mingcong Chen, Honglei Chen, Yuyan Chen, Huachen Chen, Yu Chen, Li-Juan Chen, Aozhou Chen, Xinlin Chen, Wai Chen, Dake Chen, Bo-Sheng Chen, Meilin Chen, Kequan Chen, Hong Yang Chen, Yan Chen, Bowei Chen, Silian Chen, Jian Chen, Yongmei Chen, Ling Chen, Jinbo Chen, Yingxi Chen, Ge Chen, Max Jl Chen, C Z Chen, Weitao Chen, Xiaole L Chen, Yonglu Chen, Shih-Pin Chen, Jiani Chen, Huiru Chen, San-Yuan Chen, Bing Chen, Xiao-ping Chen, Feiyue Chen, Shuchun Chen, Zhaolin Chen, Qianxue Chen, Xiaoyang Chen, Bowang Chen, Yinghui Chen, Ting-Ting Chen, Xiao-Yang Chen, Chi-Yuan Chen, Zhi-zhe Chen, Ting-Tao Chen, Xiaoyun Chen, Min-Hsuan Chen, Kuan-Ting Chen, Yongheng Chen, Wenhao Chen, Shengyu Chen, Kai Chen, Yueh-Peng Chen, Guangju Chen, Minghua Chen, Hong-Sheng Chen, Qingmei Chen, Song-Mei Chen, Limei Chen, Yuqi Chen, Yuyang Chen, Yang-Ching Chen, Yu-Gen Chen, Peizhan Chen, Rucheng Chen, Jin-Xia Chen, Szu-Chieh Chen, Xiaojun Chen, Jialing Chen, Heni Chen, Yi Feng Chen, Sen Chen, Alice Ye A Chen, Wen Chen, Han-Chun Chen, Dawei Chen, Fangli Chen, Ai-Qun Chen, Zhaojun Chen, Gong Chen, Yishan Chen, Zhijing Chen, Qiuxuan Chen, Miao-Der Chen, Fengwu Chen, Weijie Chen, Weixin Chen, Mei-Ling Chen, Hung-Po Chen, Rui-Pei Chen, Nian-Ping Chen, Tielin Chen, Canyu Chen, Xiaotao Chen, Nan Chen, C Chen, Juanjuan Chen, Xinan Chen, Jiaping Chen, Xiao-Lin Chen, Jianping Chen, Yayun Chen, Le Qi Chen, Jen-Sue Chen, Mechi Chen, Miao-Yu Chen, Zhou Chen, Szu-Han Chen, Zhen Bouman Chen, Baihua Chen, Qingao Chen, Shao-Ke Chen, Feng Chen, Jiawen Chen, Lianmin Chen, Sifeng Chen, Mengxia Chen, Xueli Chen, Can Chen, Yibo Chen, Zinan Chen, Lei-Chin Chen, Carol Chen, Yanlin Chen, Zihang Chen, Zaozao Chen, Haiqin Chen, Lu Hua Chen, Zhiyuan Chen, Meiyu Chen, Du-Qun Chen, Keying Chen, Naifei Chen, Peixian Chen, Jin-Ran Chen, Yijun Chen, Yulin Chen, Fumei Chen, Zhanfei Chen, Zhe-Yu Chen, Xin-Qi Chen, Valerie Chen, Ru Chen, Mengqing Chen, Runsheng Chen, Tong Chen, Tan-Zhou Chen, Suet Nee Chen, Cuicui Chen, Yifan Chen, Tian Chen, XiangFan Chen, Lingyi Chen, Hsiao-Yun Chen, Kenneth L Chen, Ni Chen, Huishan Chen, Fang-Yu Chen, Ken Chen, Yongshen Chen, Qiong Chen, Mingfeng Chen, Shoudeng Chen, Qiao Chen, Qian Chen, Yuebing Chen, Xuehua Chen, Chang-Lan Chen, Min-Hu Chen, Hongbin Chen, Jingming Chen, Qing Chen, Yu-Fan Chen, Hao-Zhu Chen, Yunjia Chen, Zhongjian Chen, Mingyi Chen, Qianping Chen, Huaxin Chen, Dong-Mei Chen, Peize Chen, Leijie Chen, Ming-Yu Chen, Jiaxuan Chen, Xiao-chun Chen, Wei-Min Chen, Ruisen Chen, Xuanwei Chen, Guiquan Chen, Minyan Chen, Feng-Ling Chen, Yili Chen, Alvin Chen, Xiaodong Chen, Bohong Chen, Chih-Ping Chen, Xuanjing Chen, Shuhui Chen, Ming-Hong Chen, Tzu-Yu Chen, Brian Chen, Bowen Chen, Kai-En Chen, Szu-Chia Chen, Guangchun Chen, Fang Chen, Chuyu Chen, Haotian Chen, Xiaoting Chen, Shaoliang Chen, Chun-Houh Chen, Shali Chen, Yu-Cheng Chen, Zhijun Chen, B Chen, Yuan Chen, Zhanglin Chen, Chaoran Chen, Xing-Long Chen, Zhinan Chen, Yu-Hui Chen, Yuquan Chen, Andrew Chen, Fengming Chen, Guangyong Chen, Jun Chen, Wenshuo Chen, Yi-Guang Chen, Jing-Yuan Chen, Kuangyang Chen, Mingyang Chen, Shaofei Chen, Weicong Chen, Gonghai Chen, Di-Long Chen, Limin Chen, Jishun Chen, Yunfei Chen, Caihong Chen, Tongsheng Chen, Ligang Chen, Wenqin Chen, Shiyu Chen, Xiaoyong Chen, Christina Y Chen, Yushan Chen, Ginny I Chen, Guo-Jun Chen, Xianzhen Chen, Wanling Chen, Kuan-Jen Chen, Maorong Chen, Kaijian Chen, Erqu Chen, Shen Chen, Quan Chen, Zian Chen, Yi-Lin Chen, Juei-Suei Chen, Yi-Ting Chen, Huaiyong Chen, Minjian Chen, Qianzhi Chen, Jiahao Chen, Xikun Chen, Juan-Juan Chen, Xiaobo Chen, Tianzhen Chen, Ziming Chen, Qianbo Chen, Jindong Chen, Jiu-Chiuan Chen, Yinwei Chen, Carl Pc Chen, Li-Hsin Chen, Jenny Chen, Ruoyan Chen, Yanqiu Chen, Yen-Fu Chen, Haiyan Chen, Zhebin Chen, Si Chen, Jian-Qiao Chen, Yang-Yang Chen, Ningning Chen, Zhifeng Chen, Zhenyi Chen, Hangang Chen, Zihe Chen, Mengdi Chen, Zhichuan Chen, Xu Chen, Huixi Chen, Weitian Chen, Bao-Sheng Chen, Tien-Hsing Chen, Junchen Chen, Yan-yan Chen, Xiangning Chen, Sijia Chen, Xinyan Chen, Kuan-Yu Chen, Qunxiang Chen, Guangliang Chen, Bing-Huei Chen, Fei Xavier Chen, Zhangcheng Chen, Qianming Chen, Xianze Chen, Yanhua Chen, Qinghao Chen, Yanting Chen, Sijuan Chen, Chen-Mei Chen, Qiankun Chen, Jianan Chen, Rong Chen, Xiankai Chen, Kaina Chen, Gui-Hai Chen, Y-D Ida Chen, Quanjiao Chen, Shuang Chen, Lichang Chen, Xinyi Chen, Yong-Jun Chen, Zhaoli Chen, Chunnuan Chen, Jui-Chang Chen, Zhiang Chen, Weirui Chen, Zhenguo Chen, Jennifer F Chen, Zhiguo Chen, Kunmei Chen, Huan-Xin Chen, Mengyan Chen, Dongrong Chen, Siyue Chen, Xianyue Chen, Chien-Lun Chen, YiChung Chen, Guang Chen, Quanwei Chen, Zongming E Chen, Ting-Huan Chen, Michael C Chen, Jinli Chen, Beth L Chen, Yuh-Lien Chen, Peihong Chen, Qiaoling Chen, Jiale Chen, Shufeng Chen, Xiaowan Chen, Xian-Kai Chen, Ling-Yan Chen, Yen-Ling Chen, Guiying Chen, Guangyi Chen, Yuling Chen, Xiangqiu Chen, Haiquan Chen, Cuie Chen, Gui-Lai Chen, R Chen, Heng-Yu Chen, Yongxun Chen, Fuxiang Chen, Mingmei Chen, Hua-Pu Chen, Yulong Chen, Zhitao Chen, Guohua Chen, Cheng-Yi Chen, Hongxu Chen, Yuanhao Chen, Qichen Chen, Hualin Chen, Guo-Rong Chen, Rongsheng Chen, Xuesong Chen, Wei-Fei Chen, Bao-Bao Chen, Anqi Chen, Yi-Han Chen, Ying-Jung Chen, Jinhuang Chen, Guochao Chen, Lei Chen, S N Chen, Songfeng Chen, Chenyang Chen, Xing Chen, Letian Chen, Meng Xuan Chen, Xiang-Mei Chen, Xiaoyan Chen, Yi-Heng Chen, D F Chen, Bang Chen, Jiaxu Chen, Wei Chen, Sihui Chen, Shu-Hua Chen, I-M Chen, Xuxin Chen, Zhangxin Chen, Jin Chen, Yin-Huai Chen, Wuyan Chen, Bingqing Chen, Bao-Fu Chen, Zhen-Hua Chen, Dan Chen, Zhe-Sheng Chen, Ranyun Chen, Wanyin Chen, Xueyan Chen, Xiaoyu Chen, Tai-Tzung Chen, Xiaofang Chen, Yongxing Chen, Yanghui Chen, Hekai Chen, Yuanwei Chen, Liang Chen, Hui-Jye Chen, Chengchun Chen, Han-Bin Chen, Shuaijie Chen, Yibing Chen, Kehui Chen, Shuhai Chen, Xueling Chen, Ying-Jie Chen, Qingxing Chen, Fang-Zhi Chen, Mei-Hua Chen, Yutong Chen, Lixian Chen, Alex Chen, Qiuhong Chen, Qiuxia Chen, Liping Chen, Hou-Tsung Chen, Zhanghua Chen, Chun-Fa Chen, Chian-Feng Chen, Benjamin P C Chen, Yewei Chen, Mu-Hong Chen, Jianshan Chen, Xiaguang Chen, Meiling Chen, Heng Chen, Ying-Hsiang Chen, Longyun Chen, Dengpeng Chen, Jichong Chen, Shixuan Chen, Liaobin Chen, Everett H Chen, ZhuoYu Chen, Qihui Chen, Zhiyong Chen, Nuan Chen, Hongmei Chen, Guiqian Chen, Yan Q Chen, Fengling Chen, Hung-Chang Chen, Zhenghong Chen, Chengsheng Chen, Hegang Chen, Huei-Yan Chen, Liutao Chen, Meng-Lin Chen, Xi Chen, Qing-Juan Chen, Linna Chen, Xiaojing Chen, Lang Chen, Gengsheng Chen, Fengrong Chen, Weilun Chen, Shi Chen, Wan-Yi Chen, On Chen, Yufeng Chen, Benjamin Chen, Hui-Zhao Chen, Bo-Rui Chen, Kangyong Chen, Ruixiang Chen, Weiyong Chen, Ning-Hung Chen, Meng-Ping Chen, Huimei Chen, Ying Chen, Kang-Hua Chen, Pei-zhan Chen, Liujun Chen, Hanqing Chen, Chengchuan Chen, Guojun Chen, Yongfa Chen, Li Chen, Mingling Chen, Jacinda Chen, Jinlun Chen, Kun Chen, Yi Chen, Chiung Mei Chen, Shaotao Chen, Tianhong Chen, Chanjuan Chen, Yuhao Chen, Huizhi Chen, Chung-Hsing Chen, Qiuchi Chen, Haoting Chen, Luzhu Chen, Huanhua Chen, Long Chen, Jiang-hua Chen, Kai-Yang Chen, Jing-Zhou Chen, Yong-Syuan Chen, Lifang Chen, Ruonan Chen, Meimei Chen, Qingchuan Chen, Liugui Chen, Shaokun Chen, Yi-Yung Chen, Jintian Chen, Xuhui Chen, Dongyan Chen, Huei-Rong Chen, Xianmei Chen, Jinyan Chen, Yuxi Chen, Qingqing Chen, Weibo Chen, Qiwei Chen, Mingxia Chen, Hongmin Chen, Jiahui Chen, Yen-Jen Chen, Zihan Chen, Guozhou Chen, Fei Chen, Zhiting Chen, Denghui Chen, Gary Chen, Hongli Chen, Jack Chen, Zhigang Chen, Lie Chen, Siyuan Chen, Haojie Chen, Qing-Wei Chen, Maochong Chen, Mei-Jie Chen, Haining Chen, Xing-Zhen Chen, Weiqing Chen, Huanchun Chen, C-Y Chen, Tzu-An Chen, Jen-Hau Chen, Xiaojie Chen, Dongquan Chen, Gao B Chen, Daijie Chen, Zixi Chen, Lingfeng Chen, Jiayi Chen, Zan Chen, Shuming Chen, Mei-Hsiu Chen, Xueqin Chen, Huan Chen, Xiaoqing Chen, Hui-Xiong Chen, Ruoying Chen, Deying Chen, Huixian Chen, Zhezhe Chen, Lu Chen, Xiaolong Chen, Si-Yue Chen, Xinwei Chen, Wentao Chen, Yucheng Chen, Jiajing Chen, Allen Menglin Chen, Chixiang Chen, Shiqun Chen, Wenwu Chen, Chin-Chuan Chen, Ningbo Chen, Hsin-Hung Chen, Shenglan Chen, Jia-Feng Chen, Changya Chen, ZhaoHui Chen, Guo Chen, Juhai Chen, Xiao-Quan Chen, Cuimin Chen, Yongshuo Chen, Sai Chen, Fengyang Chen, Siteng Chen, Hualan Chen, Lian Chen, Yuan-Hua Chen, Minjie Chen, Shiyan Chen, Z Chen, Zhengzhi Chen, Jonathan Chen, H Chen, You-Yue Chen, Shu-Gang Chen, Hsuan-Yu Chen, Hongyue Chen, Weiyi Chen, Jiaqi Chen, Chengde Chen, Shufang Chen, Ze-Hui Chen, Xiuping Chen, Zhuojia Chen, Zhouji Chen, Lidian Chen, Yilan Chen, Kuan-Ling Chen, Alon Chen, Zi-Yue Chen, Hongmou Chen, Fang-Zhou Chen, Jianzhou Chen, Wenbiao Chen, Yujie Chen, Zhijian Chen, Zhouqing Chen, Xiuhui Chen, Qingguang Chen, Hanbei Chen, Qianyu Chen, Mengping Chen, Yongqi Chen, Sheng-Yi Chen, Siqi Chen, Yelin Chen, Shirui Chen, Yuan-Tsong Chen, Dongyin Chen, Lingxue Chen, Long-Jiang Chen, Yunshun Chen, Yahong Chen, Yaosheng Chen, Zhonghua Chen, Jingyao Chen, Pei-Yin Chen, Fusheng Chen, Xiaokai Chen, Shuting Chen, Miao-Hsueh Chen, Y-D I Chen, Zijie Chen, Haozhu Chen, Haodong Chen, Xiong Chen, Wenxi Chen, Feng-Jung Chen, Shangwu Chen, Zhiping Chen, Zhang-Yuan Chen, Wentong Chen, Ou Chen, Ruiming Chen, Xiyu Chen, Shuqiu Chen, Xiaoling Chen, Ruimin Chen, Hsiao-Wang Chen, Dongli Chen, Haibo Chen, Yiyun Chen, Luming Chen, Wenting Chen, Chongyang Chen, Qingqiu Chen, Wen-Pin Chen, Yuhui Chen, Lingxia Chen, Jun-Long Chen, Xingyu Chen, Haotai Chen, Bang-dang Chen, Qiuwen Chen, Rui Chen, K C Chen, Zhixuan Chen, Gaoyu Chen, Yitong Chen, Tzu-Ju Chen, Jingqing Chen, Huiqun Chen, Runsen Chen, Michelle Chen, Hanyong Chen, Xiaolin Chen, Ke Chen, Yangchao Chen, Y D I Chen, Jinghua Chen, Jia Wei Chen, Man-Hua Chen, H T Chen, Zheyi Chen, Lihong Chen, Guangyao Chen, Rujun Chen, Ming-Fong Chen, Haiyun Chen, Dexiong Chen, Huiqin Chen, Ching Kit Chen, En-Qiang Chen, Wanjia Chen, Xiangliu Chen, Meiting Chen, Szu-Chi Chen, Yii-der Ida Chen, Jian-Hua Chen, Yanjie Chen, Yingying Chen, Paul Chih-Hsueh Chen, Si-Ru Chen, Mingxing Chen, Rui-Zhen Chen, Changjie Chen, Qu Chen, Yintong Chen, Jingde Chen, Mao Chen, Xinghai Chen, Mei-Chih Chen, Xueqing Chen, Chun-An Chen, Cheng Chen, Ruijing Chen, Huayu Chen, Yunqin Chen, Yan-Gui Chen, Ruibing Chen, Size Chen, Qi-An Chen, Yuan-Zhen Chen, J Chen, Heye Chen, T Chen, Junpeng Chen, Tan-Huan Chen, Shuaijun Chen, Hao Yu Chen, Fahui Chen, Lan Chen, Dong-Yi Chen, Xianqiang Chen, Shi-Sheng Chen, Qiao-Yi Chen, Pei-Chen Chen, Xueying Chen, Yi-Wen Chen, Guohong Chen, Zhiwei Chen, Zuolong Chen, Erfei Chen, Yuqing Chen, Zhenyue Chen, Qiongyun Chen, Jianghua Chen, Yingji Chen, Xiuli Chen, Xiaowei Chen, Hengyu Chen, Sheng-Xi Chen, Haiyi Chen, Shao-Peng Chen, Yi-Ru Chen, Zhaoran Chen, Xiuyan Chen, Jinsong Chen, Sunny Chen, Xiaolan Chen, S-D Chen, Ruofan Chen, Qiujing Chen, Yun Chen, Wei-Cheng Chen, Chun-Wei Chen, Liechun Chen, Lulu Chen, Hsiu-Wen Chen, Yanping Chen, Jiayao Chen, Xuejiao Chen, Guan-Wei Chen, Yusi Chen, Yijiang Chen, Chi-Hua Chen, Qixian Chen, Ziqing Chen, Peiyou Chen, Chunhai Chen, Zheren Chen, Qiuyun Chen, Xiaorong Chen, Chaoqun Chen, Dan-Dan Chen, Xuechun Chen, Yafang Chen, Mystie X Chen, Jina Chen, Wei-Kai Chen, Yule Chen, Bo Chen, Kaili Chen, Junqin Chen, Jia Min Chen, Chen Chen, Guoliang Chen, Xiaonan Chen, Guangjie Chen, Xiao Chen, Jeanne Chen, Danyang Chen, Minjiang Chen, Jiyuan Chen, Zheng-Zhen Chen, Shou-Tung Chen, Ouyang Chen, Xiu Chen, H Q Chen, Peiyu Chen, Yuh-Min Chen, Youmeng Chen, Shuoni Chen, Peiqin Chen, Xinji Chen, Chih-Ta Chen, Shang-Hung Chen, Robert Chen, Suet N Chen, Yun-Tzu Chen, Suming Chen, Ye Chen, Yao Chen, Yi-Fei Chen, Ruixue Chen, Tianhang Chen, Suning Chen, Jingnan Chen, Xiaohong Chen, Kun-Chieh Chen, Tuantuan Chen, Mei Chen, He-Ping Chen, Zhi Bin Chen, Yuewu Chen, Mengying Chen, Po-See Chen, Xue Chen, Jian-Jun Chen, Xiyao Chen, Jeremy J W Chen, Jiemei Chen, Daiwen Chen, Christina Yingxian Chen, Qinian Chen, Chih-Wei Chen, Wensheng Chen, Yingcong Chen, Zhishi Chen, Duo Chen, Jiansu Chen, Keping Chen, Min Chen, Yi-Hui Chen, Yun-Ju Chen, Gaoyang Chen, Renjin Chen, Kui Chen, Shuai-Ming Chen, Hui-Fen Chen, Zi-Yun Chen, Shao-Yu Chen, Meiyang Chen, Jiahua Chen, Zongyou Chen, Yen-Rong Chen, Huaping Chen, Yu-Xin Chen, Bohe Chen, Kehua Chen, Zilin Chen, Zhang-Liang Chen, Ziqi Chen, Yinglian Chen, Hui-Wen Chen, Peipei Chen, Baolin Chen, Zugen Chen, Kangzhen Chen, Yanhan Chen, Sung-Fang Chen, Zheping Chen, Zixuan Chen, Jiajia Chen, Yuanjian Chen, Lili Chen, Xiangli Chen, Ban Chen, Yuewen Chen, X Chen, Yan-Qiong Chen, Chider Chen, Yung-Hsiang Chen, Hanlin Chen, Xiangjun Chen, Haibing Chen, Le Chen, Xuan Chen, Xue-Ying Chen, Zexiao Chen, Chen-Yu Chen, Zhe-Ling Chen, Fan Chen, Hsin-Yi Chen, Feilong Chen, Zilong Chen, Yi-Jen Chen, Zhiyun Chen, Ning Chen, Wenxu Chen, Chuanbing Chen, Yaxi Chen, Yi-Hong Chen, Eleanor Y Chen, Yuexin Chen, Kexin Chen, Shoujun Chen, Yen-Ju Chen, Yu-Chuan Chen, Yen-Teen Chen, Bao-Ying Chen, Xiaopeng Chen, Danli Chen, Katharine Y Chen, Jingli Chen, Qianyi Chen, Zihua Chen, Ya-xi Chen, Xuanxu Chen, Chung-Hung Chen, Yajie Chen, Cindi Chen, Hua Chen, Shuliang Chen, Elizabeth H Chen, Gen-Der Chen, Bingyu Chen, Keyang Chen, Siyu S Chen, Xinpu Chen, Yau-Hung Chen, Hsueh-Fen Chen, Han-Hsiang Chen, Wei Ning Chen, Guopu Chen, Zhujun Chen, Yurong Chen, Yuxian Chen, Wanjun Chen, Qiu-Jing Chen, Qifang Chen, Yuhan Chen, Jingshen Chen, Zhongliang Chen, Ching-Hsuan Chen, Zhaoyao Chen, Yongning Chen, Marcus Y Chen, Ping Chen, Junfei Chen, Yung-Wu Chen, Xueting Chen, Yingchun Chen, Wan-Yan Chen, Yuxin Chen, Yisheng Chen, Chun-Yuan Chen, Yulian Chen, Yan-Jun Chen, Guoxun Chen, Ding Chen, Yu-Fen Chen, Jason A Chen, Shuyi Chen, Cuilan Chen, Ruijuan Chen, Kevin Chen, Xuanmao Chen, Shen-Ming Chen, Ya-Nan Chen, Sean Chen, Zhaowei Chen, Xixi Chen, Yu-Chia Chen, Xuemin Chen, Binlong Chen, Weina Chen, Xuemei Chen, Di Chen, P P Chen, Yubin Chen, Chunhua Chen, Li-Chieh Chen, Ping-Chung Chen, Zhihao Chen, Xinyang Chen, Chan Chen, Yan Jie Chen, Shi-Qing Chen, Ivy Xiaoying Chen, Ying-Cheng Chen, Jia-Shun Chen, Shao-Wei Chen, Aiping Chen, Dexiang Chen, Qianfen Chen, Hongyu Chen, Wei-Kung Chen, Danlei Chen, Hongen Chen, Shipeng Chen, Jake Y Chen, Dongsheng Chen, Chien-Ting Chen, Shouzhen Chen, Hehe Chen, Yu-Tung Chen, Yilin Chen, Joy J Chen, Zhong Chen, Zhenfeng Chen, Zhongzhu Chen, Feiyang Chen, Xingxing Chen, Keyan Chen, Huimin Chen, Guanyu Chen, D. Chen, Dianke Chen, Zhigeng Chen, Sien-Tsong Chen, Yii-Der Chen, Chi-Yun Chen, Beidong Chen, Wu-Xian Chen, Zhihang Chen, Yuanqi Chen, Jianhua Chen, Xian Chen, Xiangding Chen, Jingteng Chen, Shuaiyu Chen, Xue-Mei Chen, Yu-Han Chen, Hongqiao Chen, Weili Chen, Yunzhu Chen, Guo-qing Chen, Miao Chen, Zhi Chen, Junhui Chen, Jing-Xian Chen, Zhiquan Chen, Shuhuang Chen, Shaokang Chen, Irwin Chen, Xiang Chen, Chuo Chen, Siting Chen, Keyuan Chen, Xia-Fei Chen, Zhihai Chen, Yuanyu Chen, Po-Sheng Chen, Qingjiang Chen, Yi-Bing Chen, Rongrong Chen, Katherine C Chen, Shaoxing Chen, Lifen Chen, Luyi Chen, Sisi Chen, Ning-Bo Chen, Yihong Chen, Guanjie Chen, Li-Hua Chen, Xiao-Hui Chen, Ting Chen, Chun-Han Chen, Xuzhuo Chen, Junming Chen, Zheng Chen, Wen-Jie Chen, Bingdi Chen, Jiang Ye Chen, Yanbin Chen, Duoting Chen, Shunyou Chen, Shaohua Chen, Jien-Jiun Chen, Jiaohua Chen, Shaoze Chen, Yifang Chen, Chiqi Chen, Yen-Hao Chen, Rui-Fang Chen, Hung-Sheng Chen, Kuey Chu Chen, Y S Chen, Xijun Chen, Chaoyue Chen, Heng-Sheng Chen, Lianfeng Chen, Yen-Ching Chen, Yuhong Chen, Yixin Chen, Yuanli Chen, Cancan Chen, Yanming Chen, Yajun Chen, Chaoping Chen, F-K Chen, Menglan Chen, Zi-Yang Chen, Yongfang Chen, Hsin-Hong Chen, Hongyan Chen, Chao-Wei Chen, Jijun Chen, Xiaochun Chen, Yazhuo Chen, Zhixin Chen, YongPing Chen, Jui-Yu Chen, Mian-Mian Chen, Liqiang Chen, Y P Chen, D-F Chen, Jinhao Chen, Yanyan Chen, Chang-Zheng Chen, Shao-long Chen, Guoshun Chen, Lo-Yun Chen, Yen-Lin Chen, Bingqian Chen, Dafang Chen, Yi-Chung Chen, Liming Chen, Qiuli Chen, Shuying Chen, Chih-Mei Chen, Renyu Chen, Wei-Hao Chen, Lihua Chen, Hang Chen, Hai-Ning Chen, Hu Chen, Yu-Fu Chen, Yalan Chen, Wan-Tzu Chen, Benjamin Jieming Chen, Yingting Chen, Jiacai Chen, Ning-Yuan Chen, Shuo-Bin Chen, Yu-Ling Chen, Jian-Kang Chen, Hengsan Chen, Yu-Ting Chen, Y Chen, Qingjie Chen, Jiong Chen, Chaoyi Chen, Yunlin Chen, Gang Chen, Hui-Chun Chen, Li-Tzong Chen, Zhangliang Chen, Qiangpu Chen, Xianbo Chen, Jinxuan Chen, Hebing Chen, Ran Chen, Zhehui Chen, Carol X-Q Chen, Yuping Chen, Xiangyu Chen, Xinyu Chen, Qianyun Chen, Junyi Chen, B-S Chen, Zhesheng Chen, Man Chen, Dali Chen, Danyu Chen, Huijiao Chen, Naisong Chen, Qitong Chen, Chueh-Tan Chen, Kai-Ming Chen, Jiarou Chen, Huang Chen, Chunjie Chen, Weiping Chen, Po-Min Chen, Guang-Chao Chen, Danxia Chen, Youran Chen, Chuanzhi Chen, Peng-Cheng Chen, Wen-Tsung Chen, Linxi Chen, Si-guo Chen, Zike Chen, Zhiyu Chen, Wanting Chen, Jiangxia Chen, Wenhua Chen, Roufen Chen, Shi-You Chen, Fang-Pei Chen, Chu Chen, Feifeng Chen, Chunlin Chen, Yunwei Chen, Wenbing Chen, Xuejun Chen, Meizhen Chen, Li Jia Chen, Tianhua Chen, Xiangmei Chen, Kewei Chen, Yuh-Ling Chen, Dejuan Chen, Jiyan Chen, Xinzhuo Chen, Yue-Lai Chen, Hsiao-Jou Cortina Chen, Weiqin Chen, Huey-Miin Chen, Elizabeth Suchi Chen, Kai-Ting Chen, Lizhen Chen, Xiaowen Chen, Chien-Yu Chen, Lingjun Chen, Gonglie Chen, Jiao Chen, Zhuo-Yuan Chen, Wei-Peng Chen, Xiangna Chen, Jiade Chen, Lanmei Chen, Siyu Chen, Kunpeng Chen, Hung-Chi Chen, Jia Chen, Shuwen Chen, Siqin Chen, Zhenlei Chen, Wen-Yi Chen, Si-Yuan Chen, Yidan Chen, Tianfeng Chen, Fu Chen, Leqi Chen, Jiamiao Chen, Shasha Chen, Qingyi Chen, Ben-Kuen Chen, Haitao Chen, Qi Chen, Yihao Chen, Yunfeng Chen, Elizabeth S Chen, Yiming Chen, Youwei Chen, Lichun Chen, Yanfei Chen, Hongxing Chen, Muh-Shy Chen, Yingyu Chen, Weihong Chen, Ming Chen, Kelin Chen, Duan-Yu Chen, Shi-Yi Chen, Shih-Yu Chen, Yanling Chen, Shuanghui Chen, Ya Chen, Yusheng Chen, Yuting Chen, Shiming Chen, Xinqiao Chen, Hongbo Chen, Mien-Cheng Chen, Jiacheng Chen, Herbert Chen, Ji-ling Chen, Sun Chen, Chen-Sheng Chen, Na Chen, Chih-Yi Chen, Wenfang Chen, Yii-Der I Chen, Qinghua Chen, Shuai Chen, Hsi-Hsien Chen, F Chen, Guo-Chong Chen, Zhe Chen, Beijian Chen, Roger Chen, You-Ming Chen, Hongzhi Chen, Zhen-Yu Chen, Xianxiong Chen, Chang Chen, Chujie Chen, Chuannan Chen, Kan Chen, Lu-Biao Chen, Yupei Chen, Qiu-Sheng Chen, Shangduo Chen, Yuan-Yuan Chen, Yundai Chen, Binzhen Chen, Cai-Long Chen, Yen-Chen Chen, Xue-Xin Chen, Yanru Chen, Chunxiu Chen, Yifa Chen, Xingdong Chen, Ruey-Hwa Chen, Shangzhong Chen, Ching-Wen Chen, Danna Chen, Jingjing Chen, Yafei Chen, Dandan Chen, Pei-Yi Chen, Shan Chen, Guanghao Chen, Longqing Chen, Yen-Cheng Chen, Zhanjuan Chen, Jinguo Chen, Zhongxiu Chen, Rui-Min Chen, Shunde Chen, Xun Chen, Jianmin Chen, Linyi Chen, Ying-Ying Chen, Chien-Hsiun Chen, Li-Nan Chen, Yu-Ming Chen, Qianqian Chen, Xue-Yan Chen, Shengdi Chen, Huali Chen, Xinyue Chen, Ching-Yi Chen, Honghai Chen, Baosheng Chen, Pingguo Chen, Yike Chen, Yuxiang Chen, Qing-Hui Chen, Yuanwen Chen, Yongming Chen, Zongzheng Chen, Ruiying Chen, Huafei Chen, Tingen Chen, Zhouliang Chen, Shih-Yin Chen, Shanyuan Chen, Yiyin Chen, Feiyu Chen, Zitao Chen, Constance Chen, Zhoulong Chen, Haide Chen, Jiang Chen, Ray-Jade Chen, Shiuhwei Chen, Chih-Chieh Chen, Chaochao Chen, Lijuan Chen, Qianling Chen, Jian-Min Chen, Xihui Chen, Yuli Chen, Wu-Jun Chen, Diyun Chen, Alice P Chen, Jingxuan Chen, Chiung-Mei Chen, Shibo Chen, M L Chen, Lena W Chen, Xiujuan Chen, Christopher S Chen, Yeh Chen, Xingyong Chen, Feixue Chen, Boyu Chen, Weixian Chen, Tingting Chen, Bosong Chen, Junjie Chen, Han-Min Chen, Szu-Yun Chen, Qingliang Chen, Huatao Chen, Bin Chen, L B Chen, Xuanyi Chen, Chun Chen, Dong Chen, Yinjuan Chen, Jiejian Chen, Lu-Zhu Chen, Alex F Chen, Pei-Chun Chen, Chien-Jen Chen, Y M Chen, Xiao-Chen Chen, Tania Chen, Yang Chen, Yangxin Chen, Mark I-Cheng Chen, Haiming Chen, Shuo Chen, Yong Chen, Hsiao-Tan Chen, Erzhen Chen, Jiaye Chen, Fangyan Chen, Guanzheng Chen, Haoyun Chen, Jiongyu Chen, Baofeng Chen, Yuqin Chen, Juan Chen, Haobo Chen, Shuhong Chen, Fu-Shou Chen, Wei-Yu Chen, Haw-Wen Chen, Feifan Chen, Deqian Chen, Linlin Chen, Xiaoshan Chen, Hui Chen, Wenwen Chen, Yanli Chen, Yuexuan Chen, Xiaoyin Chen, Yen-Chang Chen, Tiantian Chen, Ruiai Chen, Alice Y Chen, Jinglin Chen, Zifan Chen, Wantao Chen, Shanshan Chen, Jianjun Chen, Xiaoyuan Chen, Xuefei Chen, Runfeng Chen, Weisan Chen, Guangnan Chen, Junpan Chen, An Chen, Lankai Chen, Yiding Chen, Tianpeng Chen, Ya-Ting Chen, Lijin Chen, Ching-Yu Chen, Y Eugene Chen, Guanglong Chen, Rongyuan Chen, Yali Chen, Yanan Chen, Liyun Chen, Shuai-Bing Chen, Zhixue Chen, Xiaolu Chen, Xiao-he Chen, Hongxiang Chen, Bing-Feng Chen, Gary K Chen, Xiaohui Chen, Jin-Wu Chen, Qiuxiang Chen, Huaqiu Chen, X Steven Chen, Xiaoqian Chen, Chao-Jung Chen, Zhengjun Chen, Yong-Ping Chen, Zhelin Chen, Xuancai Chen, Yi-Hsuan Chen, Daiyu Chen, Gui Mei Chen, Hongqi Chen, Zhizhong Chen, Mengting Chen, Guofang Chen, Jian-Guo Chen, Hou-Zao Chen, Yuyao Chen, Lixia Chen, Yu-Yang Chen, Zhengling Chen, Qinfen Chen, Jiajun Chen, Xue-Qing Chen, Shenghui Chen, Yii-Derr Chen, Linbo Chen, Yanjing Chen, S Pl Chen, Chi-Long Chen, Jiawei Chen, Rong-Hua Chen, Shu-Fen Chen, Yu-San Chen, Ying-Lan Chen, Xiaofen Chen, Weican Chen, Xin Chen, Yumei Chen, Ruohong Chen, You-Xin Chen, Tse-Ching Chen, Xiancheng Chen, Yu-Pei Chen, Weihao Chen, Baojiu Chen, Haimin Chen, Zhihong Chen, Jion Chen, Yi-Chun Chen, Ping-Kun Chen, Wan Jun Chen, Willian Tzu-Liang Chen, Qingshi Chen, Ren-Hui Chen, Weihua Chen, Hanjing Chen, Guihao Chen, Xiao-Qing Chen, Po-Yu Chen, Liangsheng Chen, Fred K Chen, Haiying Chen, Tzu-Chieh Chen, Wei J Chen, Zhen Chen, Shu Chen, Jie Chen, Chung-Hao Chen, Zi-Qing Chen, Yu-Xia Chen, Weijia Chen, Ming-Han Chen, Yaodong Chen, Yong-Zhong Chen, Jinquan Chen, Haijiao Chen, Tom Wei-Wu Chen, Jingzhou Chen, Ya-Peng Chen, Shiwei Chen, Xiqun Chen, Yingjie Chen, Wenjun Chen, Linjie Chen, Hung-Chun Chen, Xiaoping Chen, Haoran Chen, Qiang Chen, Sy-Jou Chen, Y U Chen, Weineng Chen, Li-hong Chen, Cheng-Fong Chen, Yajing Chen, Song Chen, Qiaoli Chen, Yiru Chen, Guang-Yu Chen, Zhi-bin Chen, Deyu Chen, C Y Chen, Junhong Chen, Yonghui Chen, Chaoli Chen, Syue-Ting Chen, Sufang Chen, I-Chun Chen, Shangsi Chen, Xiao-Wei Chen, Qinsheng Chen, Zhao-Xia Chen, Yun-Yu Chen, Chi-Chien Chen, Wenxing Chen, Meng Chen, Zixin Chen, Jianhui Chen, Yuanyuan Chen, Jiamin Chen, Wei-Wei Chen, Xingyi Chen, Yen-Ni Chen, Danxiang Chen, Po-Ju Chen, Mei-Ru Chen, Ziying Chen, E S Chen, Tailai Chen, Qingyang Chen, Miaomiao Chen, Shuntai Chen, Wei-Lun Chen, Xuanli Chen, Zhengwei Chen, Fengju Chen, Chengwei Chen, Xujia Chen, Faye H Chen, Xiaoxiao Chen, Shengpan Chen, Shin-Yu Chen, Shiyao Chen, Yuan-Shen Chen, Shengzhi Chen, Shaohong Chen, Ching-Jung Chen, Zihao Chen, Kaiquan Chen, Duo-Xue Chen, Xiaochang Chen, Siping Chen, Rongfeng Chen, Jiali Chen, Hsin-Han Chen, Xiaohua Chen, Delong Chen, Wenjie Chen, Huijia Chen, Yunn-Yi Chen, Siyi Chen, Zhengming Chen, Chu-Huang Chen, Zhuchu Chen, Yuanbin Chen, Jinyong Chen, Yunzhong Chen, Pan Chen, Bihong T Chen, Yunyun Chen, Shujuan Chen, M Chen, Mulan Chen, Jiaren Chen, Zechuan Chen, Jian-Qing Chen, Wei-Hui Chen, Lifeng Chen, Geng Chen, Yan-Ming Chen, Zhijian J Chen, Honghui Chen, Wenfan Chen, Zhongbo Chen, Rouxi Chen, Ye-Guang Chen, Zhimin Chen, Tzu-Ting Chen, Xiaolei Chen, Ziyuan Chen, Shilan Chen, Ruiqi Chen, Xiameng Chen, Huijie Chen, Jiankui Chen, Yuhang Chen, Jianzhong Chen, Wen-Qi Chen, Fa Chen, Shu-Jen Chen, Li-Mien Chen, Xing-Lin Chen, Xuxiang Chen, Erbao Chen, Jiaqing Chen, Hsiang-Wen Chen, Jiaxin Chen
articles
Grace E Mulia, Viviana Galindo, Ying-Cheng Chen +2 more · 2025 · Stem cell research & therapy · BioMed Central · added 2026-04-24
Acute respiratory distress syndrome (ARDS) is a lung inflammatory condition associated with the accumulation of fluid edema and cell infiltrates into the alveolar space along with dysregulation of the Show more
Acute respiratory distress syndrome (ARDS) is a lung inflammatory condition associated with the accumulation of fluid edema and cell infiltrates into the alveolar space along with dysregulation of the immune response. Current therapeutics are limited to palliative care, i.e., mechanical ventilators, thus highlighting the need to develop targeted therapeutic for ARDS. Interleukin-27 (IL-27) is a multifunctional cytokine with the capability for immune modulation. Our interest lies in exploring the properties of IL-27, particularly as an anti-inflammatory cytokine that functions as an antagonist of IL-6 signaling, as an inducer of anti-viral genes, as a promoter of tissue repair, and as a regulator of both the innate and adaptive immune responses, possessing promising potential as a therapeutic for ARDS. To overcome the challenge of repeated administration due to the short half-life of cytokines, we utilized a cell-based gene therapy approach. An IL-27-expressing plasmid was transfected into adipose mesenchymal stromal cells (ASC) that serve as the gene therapy carriers. For in vitro studies, we treated mono- and co-culture lung lipopolysaccharide (LPS)-induced lung epithelial and monocytes/macrophages cell line with IL-27-expressing ASC (IL-27 ASC) conditioned media (CM) to determine the effects on pro-inflammatory gene expression. For in vivo studies, male C57BL/6 mice were intratracheally injected with LPS (5 mg/kg) and treated either PBS, ASC, or IL-27 ASC (5 × 10 IL-27 ASC CM reduced pro-inflammatory gene expression of lung epithelial and macrophages cultured in both mono- and co-culture systems. Additionally, IL-27 ASC were able to reduce pro-inflammatory markers, decrease cell infiltration into the lungs, promote genes and immune cells involved in tissue repair, and rebalance innate and adaptive immunity in an LPS-induced in vivo model. Collectively, our in vitro and in vivo results show promising potential for IL-27 cell-based gene therapy as a treatment for ARDS. Show less
📄 PDF DOI: 10.1186/s13287-025-04647-1
IL27
Meng-Wei Lin, Chung-Hao Li, Hung-Tsung Wu +4 more · 2025 · Journal of clinical medicine · MDPI · added 2026-04-24
📄 PDF DOI: 10.3390/jcm14217599
ANGPTL4
Xian Chen, Sichen Xia, Xue Han +4 more · 2025 · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · Springer · added 2026-04-24
Cervical cancer incidence in China has risen to 13.83/100,000, particularly affecting younger women. Following recent family policy changes, reproductive concerns among cervical cancer patients have i Show more
Cervical cancer incidence in China has risen to 13.83/100,000, particularly affecting younger women. Following recent family policy changes, reproductive concerns among cervical cancer patients have intensified. While fertility-sparing treatments show good survival rates, many patients still experience significant anxiety about future fertility. This study aims to examine distinct reproductive concern profiles and their influencing factors in cervical cancer patients of childbearing age. We studied 247 patients from a Nanjing tertiary hospital between October 2023 and October 2024. Participants completed surveys including a demographic questionnaire, Reproductive Concerns After Cancer Scale, Patient Health Questionnaire-9, Benefit Finding Scale, and Fear of Cancer Recurrence Scale. Latent profile analysis (LPA) was conducted to identify reproductive concerns. Latent profile analysis revealed three distinct reproductive concern profiles: (1) a low-concern group with reproductive expectations (27.94%), (2) a moderate-concern group with self and child health preoccupations (49.39%), and (3) a high-concern group with impaired reproductive adaptation (22.67%). Significant influencing factors included age, number of children, residential location, depressive symptoms, and fear of cancer recurrence. These cross-sectional findings emphasize the need for careful consideration of individualized, multiple-disciplinary care for young women with cervical cancer. Benefit finding was associated with lower reproductive concerns. Show less
📄 PDF DOI: 10.1007/s00520-025-10125-4
LPA
Yicun Li, Yun Wu, Xiaolian Li +4 more · 2025 · Scientific reports · Nature · added 2026-04-24
Head and neck squamous cell carcinoma (HNSCC) poses a global health challenge. The management of HNSCC is complicated by the difficulty in detecting occult lymph node metastases, leading to dilemmas i Show more
Head and neck squamous cell carcinoma (HNSCC) poses a global health challenge. The management of HNSCC is complicated by the difficulty in detecting occult lymph node metastases, leading to dilemmas in elective neck dissection decisions, which will impair patients' quality of life without improving survival for nodal negative patients. We conducted a comparative analysis of the clinical features, genomic alterations, gene expression and methylation, tumor microenvironment and cellular states between the clinically N0 and pathologically N0 (cN0-pN0) patients and occult lymph node metastatic patients. Patients with occult lymph node metastases typically present with more poorly differentiated primary tumors and higher rates of angiolymphatic and perineural invasion. We identified a distinctive genomic mutation spectrum in the primary tumors of patients with occult metastases, notably in genes such as NSD1, ARHGAP15 and SMARCA4. A whole-genome DNA hypomethylation and altered gene expression profiles are identified in occult lymph node metastatic patients. Analysis of the tumor microenvironment revealed an enrichment of CARNS1 + NK cells and CBX1 + tumor cells in occult metastatic patients. In conclusion, patients with occult lymph node metastases exhibit distinct molecular and clinical features compared with cN0-pN0 patients. Show less
📄 PDF DOI: 10.1038/s41598-025-10320-7
CBX1
Changlong Zhang, Yuxuan Li, Yang Wang +6 more · 2025 · Journal of advanced research · Elsevier · added 2026-04-24
Polycystic ovary syndrome (PCOS) is frequently accompanied with metabolic dysfunctions, yet the causal relationships between metabolic factors and PCOS remain to be conclusively established and etiolo Show more
Polycystic ovary syndrome (PCOS) is frequently accompanied with metabolic dysfunctions, yet the causal relationships between metabolic factors and PCOS remain to be conclusively established and etiology-based therapies are lacking. To comprehensively identify the metabolic causal factors and potential drug targets for PCOS. This genetic association study was conducted using bidirectional two-sample Mendelian Randomization (MR), multivariable MR (MVMR) and drug-target MR. Considering metabolic sexual dimorphism, female-specific genome-wide association studies (GWASs) for metabolic factors were obtained. To ensure the robustness of the findings, an additional independent PCOS GWAS dataset was utilized for replication. The PCOS cohort included 10,074 PCOS cases (mean age 28 to 45 years) and 103,164 controls (mean age 27 to 60 years) of European ancestry. All participants were female. Employing two-sample MR analysis, we found that genetically proxied body mass index (BMI) (OR = 3.40 [95 % CI, 2.65-4.36]), triglyceride (TG) (OR = 1.54 [95 % CI, 1.17-2.04]), low-density lipoprotein cholesterol (LDL-c) (OR = 1.37 [95 % CI, 1.07-1.76]), and type 2 diabetes (T2D) (OR = 1.24 [95 % CI, 1.09-1.41]) were significantly associated with an increased risk of PCOS, whereas genetically predicted high-density lipoprotein cholesterol (HDL-c) (OR = 0.61 [95 % CI, 0.47-0.80]) decreased the odds of PCOS. Stepwise MVMR established a hierarchy of interactions among these metabolic factors, identifying BMI and HDL-c as the most prominent causal factors. Notably, drug-target MR analysis identified incretin-based therapeutics, PCSK9 inhibitors, LPL gene therapy, sulfonylureas, and thiazolidinediones as potential therapeutics for PCOS. All these findings were validated in an independent dataset. This study offered insights into the roles of obesity, diabetes, and dyslipidemia in PCOS etiology and therapeutics, underscoring the necessity for managing metabolic health in women and paving the way for tailored therapeutic strategies for PCOS based on its metabolic underpinnings. Show less
📄 PDF DOI: 10.1016/j.jare.2024.10.038
LPL
Shuanghui Chen, Yan Lu, Hao Chen +6 more · 2025 · Molecular biology and evolution · Oxford University Press · added 2026-04-24
The Kirgiz, a Turkic-speaking ethnic group with a rich nomadic heritage, represent a pivotal population for understanding human migration and adaptation in Central Asia. However, their genetic origins Show more
The Kirgiz, a Turkic-speaking ethnic group with a rich nomadic heritage, represent a pivotal population for understanding human migration and adaptation in Central Asia. However, their genetic origins and admixture history remain largely unexplored. Here, we present the first comprehensive genomic study of Kirgiz populations from Xinjiang, China (XJ.KGZ, n = 36) and their counterparts in Kyrgyzstan (KRG), integrating genome-wide data of 2,406 global individuals. Our analyses reveal four primary ancestry components in XJ.KGZ: East Asian (41.7%), Siberian (25.6%), West Eurasian (25.2%), and South Asian (7.6%). Despite close genetic affinity (FST = 0.13%), XJ.KGZ and KRG diverged ∼447 years ago, with limited gene flow post-split. A two-wave admixture model elucidates their demographic history: an initial East-West Eurasian mixture ∼2,225 years ago, likely reflecting west-east contacts during the period of the Warring States and the Qin Dynasty, followed by secondary admixture events (∼875 to 425 years ago) linked to historical migrations under Mongol and post-Mongol rule. Local adaptation signatures implicate genes critical for cellular tight junction (e.g. PATJ), pathogen invasion (e.g. OR14I1), and cardiac functions (e.g. RYR2) with allele frequency deviations suggesting ancestry-specific selection. While no classical high-altitude adaptation genes (e.g. EPAS1) showed selection signals, RYR2 and C10orf67-implicated in hypoxia response in Tibetan fauna-displayed Western ancestry bias, hinting at convergent adaptation mechanisms. This study advances our understanding of the genetic makeup and admixture history of the Kirgiz people and provides novel insights into human dispersal in Central Asia. Show less
no PDF DOI: 10.1093/molbev/msaf196
PATJ
Tong Chen, Jiawei Zhou, Mengfan Li +9 more · 2025 · BMC genomics · BioMed Central · added 2026-04-24
Pork serves as a significant meat commodity, with intramuscular fat (IMF) content being a critical determinant of its quality. However, the epigenetic mechanism of porcine IMF deposition is still uncl Show more
Pork serves as a significant meat commodity, with intramuscular fat (IMF) content being a critical determinant of its quality. However, the epigenetic mechanism of porcine IMF deposition is still unclear. This study integrated proteomics and lactylation profiles from the longissimus thoracis (LT) muscles of pigs with extremely high (IMF_H) and extremely low (IMF_L) IMF content to clarify the association between lactylation and porcine fat deposition. Furthermore, an intramuscular preadipocyte induction and differentiation model was conducted to elucidate the changes in lactylation during adipocyte differentiation. Finally, the regulatory role of lactylation in adipocyte differentiation was explored by modulating lactate production during the induction and differentiation of preadipocytes. Proteomic analysis revealed significantly increased expression of key lipid metabolism related proteins (FASN, APOA4, FABP4, ACLY, PLIN1) in IMF_H pig muscle tissues compared with IMF_L tissues, along with substantial activation of lipid metabolism pathways. Lactylation profiling identified 95 differential lysine sites across 56 proteins, with most showing lower lactylation levels in the IMF_H group. The integrative omics analysis revealed differences in lactylation profiles in porcine LT tissues with varying efficiencies of IMF deposition, highlighted PGK1, PKM, and PYGM as central lactylation-modified proteins in porcine fat deposition regulation. Further in vitro study proved that lactate-mediated lactylation inhibited adipogenic differentiation of porcine intramuscular preadipocytes through PPARγ signaling pathway. This study clarified the changes in the lactylation profile in porcine LT tissues with varying efficiencies of IMF deposition, and demonstrated that lactate-mediated lactylation inhibits the PPARγ signaling pathway and the adipogenic differentiation of porcine intramuscular preadipocyte. This study provided a new insight to understanding the epigenetic regulation mechanisms of lipid deposition in pigs. Show less
📄 PDF DOI: 10.1186/s12864-025-12428-6
APOA4
Ang-Jun Liu, Jian-Ruei Ciou, Po-Chang Wu +3 more · 2025 · International journal of rheumatic diseases · Blackwell Publishing · added 2026-04-24
This study aims to investigate the molecular differences and commonalities between systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) by analyzing RNA-sequencing (RNA-seq) data. By focusi Show more
This study aims to investigate the molecular differences and commonalities between systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) by analyzing RNA-sequencing (RNA-seq) data. By focusing on differentially expressed genes and enriched pathways, the investigation seeks to identify unique biomarkers, shared pathways, and potential therapeutic targets for these autoimmune diseases. This study involved 10 patients with SSc and 24 with SLE who did not receive immunosuppressants. RNA-seq data from patients with SSc and SLE were analyzed using DESeq2 to identify differentially expressed genes. Functional and pathway enrichment analyses were conducted and comparative analyses were performed. We identified 2055 differentially expressed genes (DEGs) between patients with SSc and controls. Notably, the expression of the shared gene RGS5 was significantly downregulated in both SLE and SSc, with a more pronounced downregulation in SSc. Additionally, the expression of the key transcription factor EGR1 was upregulated in SSc, whereas that of BLK, ITGAM, and IFNG was upregulated in SLE. Network analysis identified hub genes-AP3D1, FTX, USP47, CUX1, ZC3H4, CAND1, INTS1, TRNT1, MTERF1, and SETD1B-that may play critical roles in the progression of both SLE and SSc. These findings suggest that RGS5 could serve as a shared biomarker for vascular dysfunction, while EGR1 and BLK may represent therapeutic targets in SSc and SLE. Overall, this analysis enhances understanding of distinct and overlapping gene expression signatures in SSc and SLE, providing a foundation for future targeted treatment strategies and requiring further validation in larger cohorts. Show less
no PDF DOI: 10.1111/1756-185X.70308
ZC3H4
Yisheng Chen, Xiaofeng Chen, Zhiwen Luo +16 more · 2025 · Journal of advanced research · Elsevier · added 2026-04-24
Alzheimer's Disease (AD), a progressive neurodegenerative disorder, is marked by cognitive deterioration and heightened neuroinflammation. The influence of Insulin-like Growth Factor 1 Receptor (IGF1R Show more
Alzheimer's Disease (AD), a progressive neurodegenerative disorder, is marked by cognitive deterioration and heightened neuroinflammation. The influence of Insulin-like Growth Factor 1 Receptor (IGF1R) and its post-translational modifications, especially sumoylation, is crucial in understanding the progression of AD and exploring novel therapeutic avenues. This study investigates the impact of exercise on the sumoylation of IGF1R and its role in ameliorating AD symptoms in APP/PS1 mice, with a specific focus on neuroinflammation and innovative therapeutic strategies. APP/PS1 mice were subjected to a regimen of moderate-intensity exercise. The investigation encompassed assessments of cognitive functions, alterations in hippocampal protein expressions, neuroinflammatory markers, and the effects of exercise on IGF1R and SUMO1 nuclear translocation. Additionally, the study evaluated the efficacy of KPT-330, a nuclear export inhibitor, as an alternative to exercise. Exercise notably enhanced cognitive functions in AD mice, possibly through modulations in hippocampal proteins, including Bcl-2 and BACE1. A decrease in neuroinflammatory markers such as IL-1β, IL-6, and TNF-α was observed, indicative of reduced neuroinflammation. Exercise modulated the nuclear translocation of SUMO1 and IGF1R in the hippocampus, thereby facilitating neuronal regeneration. Mutant IGF1R (MT IGF1R), lacking SUMO1 modification sites, showed reduced SUMOylation, leading to diminished expression of pro-inflammatory cytokines and apoptosis. KPT-330 impeded the formation of the IGF1R/RanBP2/SUMO1 complex, thereby limiting IGF1R nuclear translocation, inflammation, and neuronal apoptosis, while enhancing cognitive functions and neuron proliferation. Moderate-intensity exercise effectively mitigates AD symptoms in mice, primarily by diminishing neuroinflammation, through the reduction of IGF1R Sumoylation. KPT-330, as a potential alternative to physical exercise, enhances the neuroprotective role of IGF1R by inhibiting SUMOylation through targeting XPO1, presenting a promising therapeutic strategy for AD. Show less
📄 PDF DOI: 10.1016/j.jare.2024.03.025
BACE1
Dongchen Xu, Min Wen, Bingwa Lebohang Anesu +10 more · 2025 · Journal of neuroinflammation · BioMed Central · added 2026-04-24
Ischemic stroke (IS) remains a leading cause of mortality and disability, with limited therapeutic options due to poor drug delivery to ischemic lesions. To address this challenge, an engineered Salmo Show more
Ischemic stroke (IS) remains a leading cause of mortality and disability, with limited therapeutic options due to poor drug delivery to ischemic lesions. To address this challenge, an engineered Salmonella based therapeutic method for targeted drug delivery and long-term treatment is herein designed to mitigate ischemic damage. We engineered an attenuated luminescent Salmonella typhimurium (S.t -ΔpG) strain with an L-arabinose-inducible pBAD system to secrete bioactive FGF21. C57BL/6 mice were used to to measure neuron apoptosis and the activity of immune cells following IS induction plus S.t-ΔpG injection. Bioluminescence imaging was applied for bacterial colonization. ELISA and glucose uptake assays were performed to detect FGF21 secretion and the bioactivity. Neurological tests, TTC staining, and TUNEL labeling were used to assess the therapeutic effects of barterially secreted FGF21. Immunofluorescence assay of FGF21/FGFR1 dominant pathway was explored to investigate neuroprotective mechanism, while IBA-1 staining, CD3/CD68 immunostaining, cytokine profiling, and hepatorenal histopathology were detected to evaluate biosecurity. S.t-ΔpG Our study presents a novel, Salmonella - based platform for targeted and sustained FGF21 delivery, offering a promising therapeutic strategy for ischemic stroke with robust efficacy and minimal systemic toxicity. Show less
📄 PDF DOI: 10.1186/s12974-025-03498-0
FGFR1
Xiaohuang Yang, Shaoxing Chen, Leijuan Huang +3 more · 2025 · Medicine · added 2026-04-24
Colorectal cancer (CRC) constitutes a significant public health burden in both China and the United States of America (USA), with low physical activity (LPA) identified as a key modifiable risk factor Show more
Colorectal cancer (CRC) constitutes a significant public health burden in both China and the United States of America (USA), with low physical activity (LPA) identified as a key modifiable risk factor. This study aimed to characterize temporal trends in CRC burden attributable to LPA in these 2 nations from 1990 to 2021. Using data from the 2021 global burden of disease database, age and sex-specific disparities in CRC burden attributed to LPA were evaluated in both countries. Trend analyses of age-standardized mortality rates and age-standardized disability-adjusted life year rates were performed using joinpoint regression. Decomposition analysis was applied to disentangle contributions from demographic aging, population growth, and epidemiological transitions. The age-period-cohort model was employed to quantify the independent effects of age, period, and birth cohort. Bayesian age-period-cohort modeling was utilized to project future CRC burden attributed to LPA through 2036. In 2021, LPA-attributable CRC mortality cases in China reached 16,698 (95% uncertainty interval: 10,065-24,626), exhibiting a 191.16% increase from 1990. The number of disability-adjusted life years attributed to LPA totaled 3,20,464 (95% uncertainty interval: 1,92,275-4,74,070), reflecting a 149.67% rise over the same period. Conversely, the USA reported more moderate increases of 18.26% in LPA-attributable CRC deaths and 20.28% in disability-adjusted life years. The age-period-cohort model revealed that the disease burden in both countries is shifting towards younger age groups. Further analysis of each state in the USA revealed that in 2021, the burden on low-income groups was heavier. The Bayesian age-period-cohort model predicts that the burden of CRC caused by LPA in the 2 countries will show a significant upward trend by 2036. As the burden of CRC caused by LPA becomes increasingly severe in China and the USA, there is an urgent need to raise public awareness about how physical activity can help prevent CRC and for policymakers to create targeted public health policies to lower this disease burden. Show less
no PDF DOI: 10.1097/MD.0000000000044664
LPA
Lili Qiao, Jiameng Miao, Weixuan Du +5 more · 2025 · Frontiers in clinical diabetes and healthcare · Frontiers · added 2026-04-24
Diabetes mellitus and dyslipidemia are major risk factors for atherosclerosis. Hypoechoic plaques, which indicate vulnerable or unstable plaques, may rupture and lead to ischemic stroke, cognitive imp Show more
Diabetes mellitus and dyslipidemia are major risk factors for atherosclerosis. Hypoechoic plaques, which indicate vulnerable or unstable plaques, may rupture and lead to ischemic stroke, cognitive impairment, increased adverse cardiac events, and even death. This study aimed to investigate the correlation between plasma lipid levels and the characteristics of atherosclerotic plaques in adult patients with type 2 diabetes mellitus. A retrospective analysis was conducted on adult patients with type 2 mellitus who were hospitalized in the Department of Endocrinology at Affiliated Hospital of Hebei University between January 2017 and December 2021.Patients were categorized into two groups based on arterial ultrasound results. Statistical analyses were performed to compare plasma lipid levels and plaque characteristics across the groups. 1) Statistically significant differences were observed among the two groups in terms of gender, hypertension, age, duration of diabetes mellitus, plaque location, triglycerides (TG),total cholesterol (TC), Apolipoprotein A1 (Apo A1),very-low-density lipoprotein (VLDL), VLDL/apolipoprotein B(ApoB), high-density lipoprotein cholesterol (HDL)/ApoA1 ( In clinical practice, the characteristics of atherosclerotic plaques and lipid profiles should be jointly evaluated to guide targeted treatment and effectively reduce the risk of atherosclerotic cardiovascular disease. Show less
📄 PDF DOI: 10.3389/fcdhc.2025.1688715
APOB
Lei He, Zihao Chen, Tianwei He +5 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
The balance between adipogenic and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is essential for maintaining bone homeostasis. This study aimed to investigate the role of r Show more
The balance between adipogenic and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is essential for maintaining bone homeostasis. This study aimed to investigate the role of retinoid-related orphan receptor α (RORα) in the adipogenic differentiation of BMSCs. Stable BMSC lines with RORα overexpression or knockdown were established. Adipogenic differentiation was evaluated using Oil Red O staining and by measuring the expression of adipogenic markers, including PPARγ2, LPL, LEP, FABP4, and ADIPOQ. Treatment with the RORα inhibitor SR3335 significantly promoted adipogenic differentiation, whereas the RORα agonist SR1078 exerted the opposite effect. Similarly, RORα-overexpressing (OE-RORα) BMSCs showed reduced adipogenic differentiation, while RORα knockdown BMSCs exhibited enhanced differentiation at 14 days after induction. During adipogenesis, PPARγ2 expression increased significantly, peaking at day 6 before gradually declining. Overexpression and knockdown of RORα accentuated this downregulation and upregulation, respectively, at days 6 and 12. The adipogenic marker genes lipoprotein lipase (LPL), leptin (LEP), fatty acid binding protein 4 (FABP4), and adiponectin C1Q and collagen domain containing (ADIPOQ) were markedly downregulated in RORα-overexpressing BMSCs at day 12. Moreover, RORα overexpression enhanced β-catenin nuclear translocation at day 1 post-induction and upregulated downstream WNT/β-catenin signaling molecules (Axin2, c-Myc, CD44) at day 6. Inhibition of WNT/β-catenin signaling with XAV-939 effectively reversed the suppressive effect of RORα overexpression on adipogenic differentiation and restored the expression of adipogenesis-related genes. RORα suppresses adipogenic differentiation of BMSCs, at least in part, by activating WNT/β-catenin signaling. Show less
📄 PDF DOI: 10.1186/s40001-025-03325-5
LPL
Xueli Chen, Li Dai · 2025 · Biochemical genetics · Springer · added 2026-04-24
Asthma is a common chronic respiratory disease in children, the incidence rate of which has increased in recent years. Wilms tumour 1-associated protein (WTAP) is an N6-methyladenosine (m6A) methyltra Show more
Asthma is a common chronic respiratory disease in children, the incidence rate of which has increased in recent years. Wilms tumour 1-associated protein (WTAP) is an N6-methyladenosine (m6A) methyltransferase. The purpose of this study was to explore the specific mechanism of WTAP in asthma progression, and clarify the intricate interplay between m6A modifications, WTAP, AXIN1, and their collective impact on airway smooth muscle cells (ASMCs) proliferation in asthma. Platelet-derived growth factor-BB (PDGF-BB)-treated ASMCs were used to establish an asthma model in vitro. The cell phenotype was tested using CCK-8, transwell, and wound healing assays. The expression of the Wnt signalling pathway was detected by western blotting. In addition, the relationship between WTAP/YTDHF2 and AXIN1 was assessed by a double luciferase reporter assay. Actinomycin D treatment and RT‒qPCR assays were performed to determine the mRNA stability of AXIN1. We found that WTAP was significantly increased in PDGF-BB-treated ASMCs. Knockdown of WTAP inhibited the excessive cell viability and migration of ASMCs induced by PDGF-BB. Furthermore, WTAP knockdown increased AXIN1 levels and inhibited the Wnt signalling pathway. Furthermore, WTAP knockdown decreased the m6A levels and enhanced the mRNA stability of AXIN1. WTAP overexpression showed the opposite effect. In addition, YTHDF2 was demonstrated to be the reader that recognizes the WTAP-mediated m6A modification of AXIN1. YTHDF2 knockdown enhanced the mRNA stability of AXIN1 and reversed the effect of WTAP overexpression on PDGF-BB-treated ASMCs. WTAP knockdown inhibited the excessive cell viability and migration of ASMCs by enhancing the m6A levels of AXIN1, which was further recognized by YTHDF2. The upregulation of AXIN1 mediated by the WTAP/YTHDF2 axis further inhibited the Wnt signalling pathway. Our study provides a new method for the treatment of asthma. This work not only deepens our understanding of the molecular underpinnings of asthma but also identifies potential therapeutic targets for the development of novel treatments aimed at inhibiting ASMC proliferation and alleviating asthma symptoms. Show less
📄 PDF DOI: 10.1007/s10528-024-10947-7
AXIN1
Qingcong Zheng, Rongjie Lin, Du Wang +2 more · 2025 · BMC musculoskeletal disorders · BioMed Central · added 2026-04-24
It remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between Show more
It remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between lipids, novel non-statin lipid-lowering drug target genes, and OP and BMD. Mendelian randomization (MR) method was used to explore the genetic associations between 179 lipid species and OP, BMD. Drug-target MR analysis was used to explore the causal associations between angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3) inhibitors on BMD. The IVW results with Bonferroni correction indicated that triglyceride (TG) (51:3) (OR = 1.0029; 95% CI: 1.0014-1.0045; P = 0.0002) and TG (56:6) (OR = 1.0021; 95% CI: 1.0008-1.0033; P = 0.0011) were associated with an increased risk of OP; TG (51:2) (OR = 0.9543; 95% CI: 0.9148-0.9954; P = 0.0298) was associated with decreased BMD; and ANGPTL3 inhibitor (OR = 1.1342; 95% CI: 1.0393-1.2290; P = 0.0093) and APOC3 inhibitor (OR = 1.0506; 95% CI: 1.0155-1.0857; P = 0.0058) was associated with increased BMD. MR analysis indicated causal associations between genetically predicted TGs and OP and BMD. Drug-target MR analysis showed that ANGPTL3 and APOC3 have the potential to serve as novel non-statin lipid-lowering drug targets to treat or prevent OP. Show less
📄 PDF DOI: 10.1186/s12891-024-08160-z
APOC3
Mubalake Abudoureyimu, Ni Sun, Weiwei Chen +3 more · 2025 · International journal of immunopathology and pharmacology · SAGE Publications · added 2026-04-24
This study aimed to investigate whether the dysregulation of Aurora-A is involved in lenvatinib resistance in hepatocellular carcinoma. Bioinformatics tools and drug sensitivity assays were used to in Show more
This study aimed to investigate whether the dysregulation of Aurora-A is involved in lenvatinib resistance in hepatocellular carcinoma. Bioinformatics tools and drug sensitivity assays were used to investigate the association between Aurora-A expression level and lenvatinib resistance in hepatocellular carcinoma cell lines. Cell function experiments had performed after treatment with lenvatinib and/or a selective Aurora-A inhibitor (MLN-8237). CircRNA microarray, RIP, RNA pull-down, and dual-luciferace reporter assay were performed to identify the downstream molecular mechanism of Aurora-A dysregulation. Aurora-A expression was positively correlated with lenvatinib resistance in hepatocellular carcinoma cells. The Aurora-A selective inhibitor MLN-8237, in combination with lenvatinib, synergistically inhibited hepatocellular carcinoma cell proliferation in vitro and vivo, suggesting the Aurora-A might be a potential therapeutic target for lenvatinib resistance. Mechanistically, Aurora-A induced FGFR1 expression through the hsa-circ-0058046/miR-424-5p/FGFR1 axis. Aurora-A promotes lenvatinib resistance through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma cells. The simultaneous inhibition of FGFR1 by the Aurora-A inhibitor MLN-8237 and lenvatinib overcame lenvatinib resistance in hepatocellular carcinoma cells. Collectively, our findings indicate that Aurora-A promotes lenvatinib resistance through the hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma (HCC) cells. These results suggest that Aurora-A may serve as a therapeutic target for HCC patients exhibiting lenvatinib resistance. Furthermore, the combination of lenvatinib and MLN-8237 shows potential for clinical trials aimed at overcoming lenvatinib resistance. Show less
📄 PDF DOI: 10.1177/03946320251316692
FGFR1
Xue Chen, Lili Yuan, Xiaoli Ma +8 more · 2025 · Annals of hematology · Springer · added 2026-04-24
Myeloid/lymphoid neoplasms with tyrosine kinase gene fusions (MLN-TK) are rare hematologic malignancies characterized by recurrent kinase rearrangements, including
📄 PDF DOI: 10.1007/s00277-025-06494-9
FGFR1
Zhezhe Chen, Qiongjun Zhu, Hong Xu +8 more · 2025 · Nature communications · Nature · added 2026-04-24
Many patients are suffering from atherosclerosis without typical risk factors, which can cause severe cardiovascular complications. Trimethylamine N-oxide (TMAO), derived from gut microbes, is a key u Show more
Many patients are suffering from atherosclerosis without typical risk factors, which can cause severe cardiovascular complications. Trimethylamine N-oxide (TMAO), derived from gut microbes, is a key unconventional contributor to the development of atherosclerosis. Here we present a strategy performed by orally administered nano-functionalized probiotics (PDMF@LGG) to inhibit TMAO through the gut microbiota-trimethylamine (TMA)-TMAO axis. PDMF@LGG, composed of polydopamine-coated Lacticaseibacillus rhamnosus GG and nanoparticles based on a reactive oxygen species (ROS)-responsive polymeric prodrug of fluoromethylcholine (FMC), can promote the retention of probiotics and nanoparticles in the intestine to persistently scavenge elevated ROS and release drugs. This process suppresses TMA production and absorption, lowering plasma TMAO levels. The therapeutic effects on male ApoE Show less
📄 PDF DOI: 10.1038/s41467-025-66448-7
APOE
Hui Yan, Rui Wang, Suryavathi Viswanadhapalli +35 more · 2025 · Science advances · Science · added 2026-04-24
B cells express many protein ligands, yet their regulatory functions are incompletely understood. We profiled ligand expression across murine B sublineage cells, including those activated by defined r Show more
B cells express many protein ligands, yet their regulatory functions are incompletely understood. We profiled ligand expression across murine B sublineage cells, including those activated by defined receptor signals, and assessed their regulatory capacities and specificities through in silico analysis of ligand-receptor interactions. Consequently, we identified a B cell subset that expressed cytokine interleukin-27 (IL-27) and chemokine CXCL10. Through the IL-27-IL-27 receptor interaction, these IL-27/CXCL10-producing B cells targeted CD40-activated B cells in vitro and, upon induction by immunization and viral infection, optimized antibody responses and antiviral immunity in vivo. Also present in breast cancer tumors and retained there through CXCL10-CXCR3 interaction-mediated self-targeting, these cells promoted B cell PD-L1 expression and immune evasion. Mechanistically, Show less
📄 PDF DOI: 10.1126/sciadv.adx9917
IL27
Xiujin Shen, Haibing Wang, Chunhua Weng +7 more · 2025 · Kidney international · Elsevier · added 2026-04-24
Angiopoietin-like 4 (Angptl4) is a secreted protein that participates in multiple biological processes. Our previous study on the effect of Angptl4 in minimal change disease (MCD) unexpectedly indicat Show more
Angiopoietin-like 4 (Angptl4) is a secreted protein that participates in multiple biological processes. Our previous study on the effect of Angptl4 in minimal change disease (MCD) unexpectedly indicated a close correlation between Angptl4 and kidney function, especially in MCD patients combined with AKI, implying a possible function of Angptl4 in AKI. However, the role and molecular mechanism of Angptl4 in AKI are undetermined. Biopsy tissue and serum of patients with AKI were analyzed by ELISA and immunohistochemistry to evaluate ANGPTL4 expression and its correlation with kidney function. For in vitro study, ANGPTL4 overexpressed and knocked down HK-2 cells were used to determine the effect of ANGPTL4 on cell pyroptosis. For in vivo study, Angptl4 global and conditional knockout mice were generated to study AKI using cisplatin- or ischemia/reperfusion-induced AKI mouse models. Additionally, we used various experimental approaches to investigate how ANGPTL4 induces tubular cell injury via interaction with integrin β. Angptl4 was up regulated in kidney tubular epithelial cells of multiple AKI models and correlated with kidney function. ANGPTL4 aggravated tumor suppressor GSDME-dependent cell pyroptosis in vitro. In genetic mice, overexpression of Angptl4 worsened kidney function, inflammation, and cell pyroptosis, whereas ablation of Angptl4 attenuated kidney injury in AKI. Mechanistically, ANGPTL4 interacted with integrin β5 and activated focal adhesion kinase (FAK), promoting kidney tubular pyroptosis through the caspase 3/GSDME signaling pathway. Inhibition of integrin β5 or FAK alleviated kidney tubular pyroptosis and kidney dysfunction. Moreover, ANGPTL4 promoted the secretion of cytokines MCP-1 and RANTES by kidney tubular epithelial cells, enhancing macrophage recruitment. Our results reveal that Angptl4 triggers pyroptosis and worsened kidney injury in AKI and offers a potential target for the diagnosis and treatment of AKI. Show less
no PDF DOI: 10.1016/j.kint.2025.07.025
ANGPTL4
Yian Chen, Haining Ding, Jiaqing Song +1 more · 2025 · Cancer cell international · BioMed Central · added 2026-04-24
A crucial aspect of the association involving inflammation and the development of cancer is the ability of cancer cells to undergo a transition into mesenchymal cells. The process is referred to as ep Show more
A crucial aspect of the association involving inflammation and the development of cancer is the ability of cancer cells to undergo a transition into mesenchymal cells. The process is referred to as epithelial-mesenchymal transition (EMT). Cytokines and chemokines, which are inflammatory agents found in the carcinoma microenvironment, induce epithelial-mesenchymal transition (EMT) changes in malignant cells. Evaluating the role of cytokines in EMT in breast carcinoma and investigating their potential therapeutic implications is the objective of this comprehensive research report. The following search criteria were applied to the Cochrane, Embase, PubMed, and Web of Science databases: "cytokines," "the cytokines," "chemokines," "EMT," "epithelial-mesenchymal transition or transformation," "breast tumor," "breast carcinoma," and "breast cancer." A body of research comprising 54 articles has demonstrated that a number of cytokines, including TNF-α, TGF-β, and IL-6, contribute to the promotion of EMT alterations in breast tumors. The epithelial markers E-cadherin and β-catenin were downregulated as a consequence of morphological changes induced by EMT; conversely, the mesenchymal markers N-cadherin, vimentin, and fibronectin were upregulated. The EMT transforming factors (EMT-TF) TWIST/ZEB/SNAI1/SNAI2 were upregulated. Pharmaceuticals with the capacity to specifically target cytokines or their epithelial-mesenchymal transition (EMT) signalling pathways have the potential to significantly reduce treatment resistance, impede the progression of cancer, and prevent the recurrence of breast cancer. Epithelial-mesenchymal transition (EMT) induced by cytokines is a factor in breast cancer progression and metastasis. Show less
no PDF DOI: 10.1186/s12935-025-03973-x
SNAI1
Mackenzie K Fitzpatrick, Alexandria Szalanczy, Angela Beeson +8 more · 2025 · Obesity (Silver Spring, Md.) · Wiley · added 2026-04-24
Adenylate cyclase 3 (Adcy3) has been linked to both obesity and major depressive disorder. We identified a protein-coding variant in the transmembrane (TM) helix of Adcy3 in rats; similar obesity vari Show more
Adenylate cyclase 3 (Adcy3) has been linked to both obesity and major depressive disorder. We identified a protein-coding variant in the transmembrane (TM) helix of Adcy3 in rats; similar obesity variants have been identified in humans. This study investigates the role of a TM variant in adiposity and behavior. We mutated the TM domain of Adcy3 (Adcy3 Adcy3 The ADCY3 TM domain plays a role in protein function via p-AMPK and CREB signaling. Adcy3 may contribute to the relationship between obesity and major depressive disorder, and sex influences the relationships between Adcy3, metabolism, and behavior. Show less
📄 PDF DOI: 10.1002/oby.24178
ADCY3
Yajie Zhang, Yang Li, Wentao Huang +7 more · 2025 · International journal of surgery (London, England) · added 2026-04-24
Gastroesophageal reflux disease (GERD) and asthma are commonly co-occurring conditions, with shared genetic factors identified. However, the specific loci and the influence of common genetic architect Show more
Gastroesophageal reflux disease (GERD) and asthma are commonly co-occurring conditions, with shared genetic factors identified. However, the specific loci and the influence of common genetic architecture remain undefined. We obtained genome-wide association study (GWAS) summary statistics for GERD (71 522 cases and 261 079 controls) and asthma (56 167 cases and 352 255 controls). Using linkage disequilibrium score regression (LDSC), we assessed genetic correlations between GERD and asthma. Bidirectional Mendelian randomization (MR) was performed to investigate potential causal relationships, followed by cross-trait GWAS meta-analysis and colocalization analysis to identify shared risk loci. Additionally, summary-data-based MR and transcriptome-wide association study were conducted to pinpoint common functional genes. Finally, we analyzed gene expression profiles in both healthy individuals and GERD patients using esophageal single-cell RNA sequencing (scRNA-seq) data. We identified a significant genetic correlation between GERD and asthma ( rg  = 0.37, P = 6.19 × 10 -38 ) and a significant causal effect of GERD on asthma [odds ratio (OR) = 1.22, P = 1.54 × 10 -5 ]. Cross-trait meta-analyses revealed 56 shared risk loci between GERD and asthma, including 51 loci that were newly identified. Three loci (rs61937247, rs7960225, and rs769670) exhibited evidence of colocalization. Gene-level analyses pinpointed three novel shared genes ( RBM6, SUOX , and MPHOSPH9 ) between GERD and asthma. scRNA-seq analysis uncovered heightened expression of these genes in immune cells of patients diagnosed with GERD. Our study has discovered novel shared genetic loci and candidate genes between GERD and asthma, providing further insights into the genetic susceptibility of comorbidity and potential mechanisms of the two diseases. Show less
no PDF DOI: 10.1097/JS9.0000000000003283
RBM6
Roshni Jaffery, Yuhang Zhao, Sarfraz Ahmed +12 more · 2025 · NPJ Parkinson's disease · Nature · added 2026-04-24
Mutations in LRRK2, a leading genetic cause of Parkinson's disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incomplete Show more
Mutations in LRRK2, a leading genetic cause of Parkinson's disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples (n = 651) and matched CSF samples (n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies. Show less
📄 PDF DOI: 10.1038/s41531-025-01215-5
IL27
Chi Chen, Yimeng Gu, Junfei Xu +9 more · 2025 · Scientific reports · Nature · added 2026-04-24
Apolipoprotein B (apoB) can be measured directly and accurately, and better predicts atherogenic risk than conventional lipid profiles. We aimed to investigate whether total and regional (trunk or leg Show more
Apolipoprotein B (apoB) can be measured directly and accurately, and better predicts atherogenic risk than conventional lipid profiles. We aimed to investigate whether total and regional (trunk or leg) fat deposits are associated with apoB levels in general US adults. 4585 participants were enrolled from the US National Health and Nutritional Surveys from 2011 to 2016. Overall and regional body fat were measured using dual-energy X-ray absorptiometry. The associations of total and regional fat with apoB levels were evaluated using linear regression models. Following adjustment for demographic, lifestyle, and clinical risk factors, whole-body fat percentage was positively associated with apoB levels. Additionally, percent trunk fat was positively associated (highest vs. lowest tertile beta = 17.73 for men and 14.89 for women, respectively), whereas percent leg fat was inversely associated (highest vs. lowest tertile beta = - 4.84 for men and - 6.55 for women, respectively) with apoB levels in both sexes. The association for trunk fat and leg fat remained significant after further adjustment for body mass index or waist circumference. Higher percent trunk fat combined with lower percent leg fat was associated with particularly higher apoB. In conclusion, among general US adults, both elevated trunk fat and reduced leg fat are associated with higher levels of apoB. Further research is required to elucidate the underlying pathophysiological mechanisms. Show less
📄 PDF DOI: 10.1038/s41598-025-10502-3
APOB
Yuxin Fan, Jiandong Yuan, Lichun Dong +12 more · 2025 · Diabetes, obesity & metabolism · Blackwell Publishing · added 2026-04-24
Previous experiments have demonstrated that BGM0504, a GLP-1R/GIPR dual agonist drug by molecular dynamics-guided optimization, had enhanced agonistic activity compared to tirzepatide. This study aims Show more
Previous experiments have demonstrated that BGM0504, a GLP-1R/GIPR dual agonist drug by molecular dynamics-guided optimization, had enhanced agonistic activity compared to tirzepatide. This study aims to investigate its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese healthy volunteers. A randomized, double-blind, placebo-controlled and dose-escalation Phase I study was conducted as follows: a single dose (2.5 mg) and once-weekly administration for 2 weeks to reach target doses (5, 10 and 15 mg) by titration. A total of 40 volunteers received at least one dose of BGM0504 or placebo. The PK profile of BGM0504 was investigated over a wide dose range and supported once-weekly administration. It was observed that C BGM0504 was generally safe and well tolerated with favourable PK profile and potential role in weight loss was also confirmed. These findings support subsequent development of BGM0504 for type 2 diabetes mellitus (T2DM) and obesity. Show less
no PDF DOI: 10.1111/dom.16203
GIPR
Hongzhi Li, Xian Gao, Chengde Chen +4 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
Lung adenocarcinoma (LUAD) is a leading cause of cancer deaths. Given that traditional pathologic features to diagnose LUAD do not fully reflect the biological differences in patients, the search for Show more
Lung adenocarcinoma (LUAD) is a leading cause of cancer deaths. Given that traditional pathologic features to diagnose LUAD do not fully reflect the biological differences in patients, the search for novel biomarkers is necessary. In this study, we obtained immune-related genes (IRGs) from ImmPort and performed cluster analysis on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to mine LUAD subtypes with different immune characteristics. Quantitative analysis of IRGs was performed by single-sample gene set enrichment analysis (ssGSEA). Based on the univariate cox and LASSO regression methods, we screened the characteristic genes that significantly affected LUAD and built the model based on the RiskScore coefficients. The relative expressions of characteristic genes in LUAD were determined using qRT-PCR. Transwell and wound healing assays were utilized to verify the practical regulation of these genes on the migration and invasion levels of LUAD. Correlations were established between RiskScore and LUAD drug sensitivity by oncoPredict. We acquired three LUAD subtypes and demonstrated heterogeneous IRGs scores and clinical features. The molecular subtypes were differentially enriched in bile acid metabolism, fatty acid metabolism, and ECM-receptor interaction. This study identified seven genes (MS4A1, EXO1, CPS1, ZNF750, S100P, NT5E, KCNN4) as a signature affecting prognosis, from the differentially expressed genes (DEGs) among the molecular subtypes, and constructed a RiskScore for the prognosis of LUAD. Cellular experiments verified that 6 of 7 characteristic genes were expression dysregulation in LUAD cell line. Silencing of EXO1 significantly suppressed the migration and invasion of LUAD cell lines. RiskScore and immune checkpoints such as CD276, TNFSF4, and TNFSF9 showed a positive correlation. This study identified three LUAD subtypes with distinct immune characteristics and constructed a seven-gene prognostic model. This model correlates with immune checkpoint and chemotherapy sensitivity, providing new targets and strategies for clinical diagnosis and treatment. Show less
📄 PDF DOI: 10.1186/s40001-025-03544-w
CPS1
Yu-Fan Chen, Chien-Wei Lee, Yi-Shuan J Li +8 more · 2025 · Experimental & molecular medicine · Nature · added 2026-04-24
Macrophages play a crucial role in coordinating the skeletal muscle repair response, but their phenotypic diversity and the transition of specialized subsets to resolution-phase macrophages remain poo Show more
Macrophages play a crucial role in coordinating the skeletal muscle repair response, but their phenotypic diversity and the transition of specialized subsets to resolution-phase macrophages remain poorly understood. Here, to address this issue, we induced injury and performed single-cell RNA sequencing on individual cells in skeletal muscle at different time points. Our analysis revealed a distinct macrophage subset that expressed high levels of Gpnmb and that coexpressed critical factors involved in macrophage-mediated muscle regeneration, including Igf1, Mertk and Nr1h3. Gpnmb gene knockout inhibited macrophage-mediated efferocytosis and impaired skeletal muscle regeneration. Functional studies demonstrated that GPNMB acts directly on muscle cells in vitro and improves muscle regeneration in vivo. These findings provide a comprehensive transcriptomic atlas of macrophages during muscle injury, highlighting the key role of the GPNMB macrophage subset in regenerative processes. Our findings suggest that modulating GPNMB signaling in macrophages may represent a promising avenue for future research into therapeutic strategies for enhancing skeletal muscle regeneration. Show less
no PDF DOI: 10.1038/s12276-025-01467-4
NR1H3
Hua Chen, Cailing Han, Chunfang Ha · 2025 · Applied biochemistry and biotechnology · Springer · added 2026-04-24
Uterine corpus endometrial carcinoma (UCEC) is one of the most common gynecologic tumors. Due to the high recurrence and metastasis of UCEC, it is crucial for patients to find new biomarkers for diagn Show more
Uterine corpus endometrial carcinoma (UCEC) is one of the most common gynecologic tumors. Due to the high recurrence and metastasis of UCEC, it is crucial for patients to find new biomarkers for diagnosis and therapy. In this study, R software and the TCGA database were used to screen candidate UCEC predictive markers. Western blot and RT-qPCR were performed to detect protein and mRNA expression of EXT1 in UCEC cell lines. In addition, MTT assay, flow cytometry, transwell assay, and wound healing assay were conducted to assess the cell viability, apoptosis, invasion, and migration in UCEC cells. Overlap-extension PCR technique was employed to construct the vector targeting the deletion of the methylated segment of EXT1. The results showed that a total of 11 candidate genes were obtained and EXT1 was identified as a potential target. The expression and methylation levels of EXT1 were both increased in UCEC tissues and cell lines, as well as elevated EXT1 was closely related to the poor prognosis of patients. Besides, the knockdown of EXT1 significantly inhibited the malignant biological behaviors in UCEC cells. Additionally, the current study also found that the deletion of 1559-2146 bp CpG island segment upregulated EXT1 expression and promoted malignant biological behaviors in UCEC cells. Furthermore, the presence of m7G RNA methylation in UCEC cells also was found. In conclusion, the methylation of EXT1 influenced the gene expression, thereby affecting the malignant biological behaviors in UCEC cells and regulating the pathological progression of UCEC. Show less
📄 PDF DOI: 10.1007/s12010-024-05116-w
EXT1
Junyang Chen, Boya Liu, Xinlei Yao +8 more · 2025 · CNS neuroscience & therapeutics · Blackwell Publishing · added 2026-04-24
The AMPK/SIRT1/PGC-1α pathway serves as a central regulator of cellular energy homeostasis, coordinating metabolic stress responses, epigenetic modifications, and transcriptional programs. Its dysfunc Show more
The AMPK/SIRT1/PGC-1α pathway serves as a central regulator of cellular energy homeostasis, coordinating metabolic stress responses, epigenetic modifications, and transcriptional programs. Its dysfunction is implicated in the pathogenesis of a wide spectrum of complex modern diseases, spanning neurodegeneration, metabolic syndromes, and chronic inflammatory conditions. This review examines the pathway's role as an integrative hub and its potential as a therapeutic target. We synthesize current mechanistic evidence from molecular, cellular, and preclinical studies to elucidate the pathway's operational logic and the consequences of its dysregulation. The analysis is structured around key disease paradigms-including Alzheimer's disease, Parkinson's disease, diabetes, cardiovascular injury, stroke, and chronic kidney disease-to dissect its tissue-specific pathophysiological impacts. The AMPK/SIRT1/PGC-1α axis operates through a core positive feedback loop: AMPK activation elevates NAD+, thereby activating SIRT1, which in turn deacetylates and activates PGC-1α to drive mitochondrial biogenesis and function, further reinforcing SIRT1 activity. Disruption of this cascade manifests in disease-specific mechanisms: promoting Aβ production via BACE1/γ-secretase in Alzheimer's; impairing α-synuclein clearance in Parkinson's; disrupting GLUT4 translocation and insulin signaling in diabetes; exacerbating oxidative damage and mitochondrial dysfunction in cardiovascular and neuronal injury; and accelerating fibrosis and sustained inflammation in renal and pulmonary diseases via NLRP3 and TGF-β/Smad3 signaling. The AMPK/SIRT1/PGC-1α pathway represents a cornerstone target at the intersection of metabolism, aging, and disease. Current therapeutic strategies-including pharmacological activators (e.g., metformin, SRT1720), natural compounds (e.g., resveratrol), lifestyle interventions (e.g., exercise, caloric restriction), and emerging technologies (e.g., gene editing, exosomal miRNAs)-offer multidimensional avenues for intervention. Future research must prioritize elucidating tissue-specific regulatory mechanisms, such as AMPK isoform diversity and PGC-1α interactome dynamics, to enable precision therapeutics and successful clinical translation for a range of complex disorders. Show less
📄 PDF DOI: 10.1111/cns.70657
BACE1